Melanoma, therapy
- Name
- Melanoma, therapy
- Accession Number
- DBCAT005183
- Description
Not Available
- Drugs
Drug Drug Description IMM-101 IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies... Tebentafusp A bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma. - Drugs & Drug Targets
Drug Target Type Tebentafusp Melanocyte protein PMEL target